Study of a new tumor marker, CYFRA 21-1, in squamous cell carcinoma of the cervix, and comparison with squamous cell carcinoma antigen.
The diagnostic value of a new tumor marker, CYFRA 21-1, was studied in the blood samples collected from 22 controls, and 87 pre-treatment patients with squamous cell carcinoma of the cervix. Sensitivity and specificity of CYFRA 21-1 was compared with those of squamous cell carcinoma antigen (SCC) measured in the sera of the same patients. Serum CYFRA 21-1 levels were higher in patients with squamous cell carcinoma than in controls (p < 0.05), and correlated with FIGO stage (Stage IIb-IV vs. Stage Ib-IIa, p = 0.0477). Using 2.5 ng/ml as cut-off value, elevated CYFRA 21-1 levels were found in 13.6% of controls, 34.8% of patients with Stage Ib-IIa squamous cell carcinoma of the cervix, and 63.5% of patients with Stage IIb-IV squamous cell carcinoma of the cervix. However, there was less sensitivity and specificity of CYFRA 21-1 than those of SCC in detecting squamous cell carcinoma of the cervix. CYFRA 21-1 may not be a better tumor marker than SCC for squamous cell carcinoma of the cervix.
Tsai
S C
SC
Department of Nuclear Medicine, Taichung Veterans General Hospital, Taiwan, R.O.C.
Kao
C H
CH
Wang
S J
SJ
D000368:Aged; D000951:Antigens, Neoplasm / Q000097:blood*; D014408:Biomarkers, Tumor / Q000097:blood*; D002294:Carcinoma, Squamous Cell / Q000097:blood*; D005260:Female; D006801:Humans; D007633:Keratins / Q000097:blood*; D008875:Middle Aged; D010446:Peptide Fragments / Q000097:blood*; D012016:Reference Values; D015843:Serpins; D002583:Uterine Cervical Neoplasms / Q000097:blood*
D000951:Antigens, Neoplasm; D014408:Biomarkers, Tumor; D010446:Peptide Fragments; D015843:Serpins; C051072:squamous cell carcinoma-related antigen; D007633:Keratins